BioXcel Therapeutics (BTAI) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), BioXcel Therapeutics had return on equity of 74.1% (down from 79.7%), debt-to-equity of -0.89 (up from -1.10), a current ratio of 0.83 (down from 1.68) and return on assets of -121.2% (down from -120.0%). A current ratio of 0.83 means current liabilities exceed current assets.

BioXcel Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Income Statement Balance Sheet Cash Flow Ratios

Scroll to see more

Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Valuation Ratios
P/S Ratio	55.65	8.19	63.98	1612.26	-	-
P/B Ratio	-0.37	-0.20	-1.56	7.87	2.57	5.45
Price/Tangible Book	-	-	-	7.84	2.42	5.45
Enterprise Value Ratios
EV/Revenue	181.56	40.28	89.94	1345.89	-	-
Profitability & Returns
Return on Equity (ROE)	74.14%	79.67%	-1766.94%	-111.08%	-49.93%	-70.35%
Return on Assets (ROA)	-121.22%	-120.04%	-122.90%	-71.70%	-46.56%	-40.13%
Return on Invested Capital (ROIC)	-386.58%	-5373.15%	-7560.83%	-5689.42%	-3889.96%	-
Return on Capital Employed (ROCE)	-1422.44%	-215.05%	-156.60%	-80.68%	-49.64%	-39.50%
Leverage & Solvency Ratios
Debt/Equity	-0.89	-1.10	-1.79	1.22	0.01	0.01
Liquidity Ratios
Current Ratio	0.83	1.68	2.65	6.17	14.21	18.33
Quick Ratio	0.54	1.35	2.39	5.90	13.98	18.00
Efficiency Ratios
Asset Turnover	0.02	0.04	0.01	0.00	0.00	-
Inventory Turnover	0.23	1.61	0.63	0.02	-	-
Yield & Distribution Ratios
Earnings Yield	-	-	-	-	-	-7.30%
FCF Yield	-	-	-	-	-	-5.92%
Buyback Yield	-381.58%	-39.21%	-4.00%	-6.23%	-21.63%	-33.11%
Total Return	-381.58%	-39.21%	-4.00%	-6.23%	-21.63%	-

Source: Company financial statements from annual and quarterly filings. Data as of Mar 31, 2026. Data sources and methodology

Frequently Asked Questions About BioXcel Therapeutics Financial Ratios

What is BioXcel Therapeutics's return on equity?

BioXcel Therapeutics's return on equity (ROE) was 74.1% for fiscal 2025 (period ended Dec 31, 2025). It was 79.7% a year earlier.

What is BioXcel Therapeutics's debt-to-equity ratio?

BioXcel Therapeutics's debt-to-equity ratio was -0.89 for fiscal 2025 (period ended Dec 31, 2025). It was -1.10 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition